Who are Tempest Therapeutics, Inc.'s main suppliers?

Tempest Therapeutics, Inc. (TPST) key suppliers include: ERIGEN, FACTOR-BIOSCIENCE-LIMITED, H-C-WAINWRIGHT-CO-LLC, NOVATIM, FACTOR and 5 more. View the full supplier network at chainsifter.com/chain/TPST.

Who are Tempest Therapeutics, Inc.'s major customers?

Tempest Therapeutics, Inc. (TPST) key customers include: Myriad Genetics, Inc., Myriad Genetics, Inc., COMPANY-COMPUTERSHARE-INC, COMPUTERSHARE-TRUST-COMPANY, MILLENDO-THERAPEUTICS-INC and 1 more. View the full customer network at chainsifter.com/chain/TPST.

What sector is Tempest Therapeutics, Inc. in?

Tempest Therapeutics, Inc. (TPST) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Tempest Therapeutics, Inc. Supplier List (TPST): 10 Verified Suppliers

10Suppliers

6Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Tempest Therapeutics, Inc. (TPST) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships

3Distinct source URLs

10High confidence

0.791Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Tempest Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ERIGEN	ERIGEN	92%	On February 3, 2026, the Company completed the acquisition of the Erigen Assets (the 'Erigen Closing') under the Asset Purchase Agreement (the 'Asset Acquisition') and issued to Erigen 8,268,495 shar…
FACTOR-BIOSCIENCE-LIMITED	FACTOR-BIOSCIENCE-LIMITED	92%	We are obligated to pay Factor Bioscience Limited up to $40 million in total upon achievement of certain development milestones for the programs.
H-C-WAINWRIGHT-CO-LLC	H-C-WAINWRIGHT-CO-LLC	92%	Pursuant to an engagement letter, H.C. Wainwright & Co., LLC (the “ Placement Agent ”) acted as the exclusive placement agent in connection with the foregoing transaction, and the Company issued to t…
NOVATIM	NOVATIM	92%	We are obligated to pay Novatim up to $80 million in total upon achievement of certain development milestones for the programs and up to $1.24 billion in total upon achievement of certain commercial …
FACTOR	FACTOR	85%	Pursuant to the Asset Purchase Agreement, Factor has made a funding commitment (the 'Funding Commitment') to provide the Company
COMPUTERSHARE-TRUST-COMPANY-NA	COMPUTERSHARE-TRUST-COMPANY-NA	80%	The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the 'Rights Agreement'), between the Company and Computershare Trust Company, NA.
CMOS	CMOS	75%	We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
CROS	CROS	75%	We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
EQUIPMENT-AND-REAGENT-VENDORS	EQUIPMENT-AND-REAGENT-VENDORS	75%	We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX g…

Tempest Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from TPST graph: cting biopharmaceutical companies, and U.S. laws and regulations affecting biopharmaceutical companies based in or op…
MYGN	Myriad Genetics, Inc.	72%	cting biopharmaceutical companies, and U.S. laws and regulations affecting biopharmaceutical companies based in or operating in China are also unpredictable. Any regulatory changes and changes in Uni…
COMPANY-COMPUTERSHARE-INC	COMPANY-COMPUTERSHARE-INC	62%	l-targeting CAR T-cell therapy known as TPST-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as TPST-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy wi…
COMPUTERSHARE-TRUST-COMPANY	COMPUTERSHARE-TRUST-COMPANY	62%	l-targeting CAR T-cell therapy known as TPST-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as TPST-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy wi…
MILLENDO-THERAPEUTICS-INC	MILLENDO-THERAPEUTICS-INC	62%	The risks we face in connection with acquisitions, include: • diversion of management time and focus from operating our business to addressing acquisition integration challenges; • coordination of re…
OXFORD-FINANCE-LLC	OXFORD-FINANCE-LLC	62%	expenses incurred to advance our research and development activities. The largest component of our operating expenses has historically been the investment in research and development activities. We e…

Tempest Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TPST-DEBT-13083	Warrants outstanding: 6784989	90%	xbrl warrant detail from xbrl 2026-02-03.
TPST-DEBT	Debt stack $199,000	90%	Market cache reports total debt of $199,000.
TPST-DEBT-13084	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-12-31.

Tempest Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tempest Therapeutics, Inc..

Tempest Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TPST-OWNER-VERSANT-VENTURE-MANAGEMENT-LLC	Versant Venture Management, LLC	90%	13F overlay lists Versant Venture Management, LLC as top holder; 1 tracked holders.

Tempest Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
IMNM	Immunome, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	2
COGT	Cogent Biosciences, Inc.	100.00	2
GSK	GSK plc	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
BIAF	bioAffinity Technologies, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
RXRX	Recursion Pharmaceuticals, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	2
ATYR	aTyr Pharma, Inc.	100.00	2
KDK	Kodiak AI, Inc.	100.00	2

Tempest Therapeutics, Inc. Supply Chain